HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation

HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance

(2013) W. Q. Sheng et al.   ANNALS OF ONCOLOGY

Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China

(2013) Miao-zhen Qiu et al.   Journal of Translational Medicine

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

(2013) Tao Qin et al.   OncoTargets and Therapy

Advanced HER2-positive gastric cancer: Current and future targeted therapies

(2012) Roberto A. Pazo Cid et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment

(2012) Kohei Shitara et al.   Gastric Cancer

HER2 expression and its clinicopathological features in resectable gastric cancer

(2012) Yoshiki Kataoka et al.   Gastric Cancer

HER2/neutesting for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

(2012) Carlos Gómez-Martin et al.   JOURNAL OF CLINICAL PATHOLOGY

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

(2012) Jan Trøst Jørgensen et al.   Journal of Cancer

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

(2011) Kab Choong Kim et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome

(2011) Maria D. Begnami et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of HER-2 Overexpression/Amplification on the Prognosis of Gastric Cancer Patients Undergoing Resection: A Single-Center Study of 1,036 Patients

(2011) J.-T. Hsu et al.   ONCOLOGIST

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

(2009) J D Barros-Silva et al.   BRITISH JOURNAL OF CANCER

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

(2009) Xiu Li Zhang et al.   WORLD JOURNAL OF SURGERY

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE